Abstract
In this work, the experimental solubility of ethyl candesartan in the selected solvents within the temperature ranging from 278.15 to 318.15 K was studied. It can be easily found that the solubility of ethyl candesartan increases with the rising temperature in all solvents. The maximum solubility value was obtained in N,N-dimethylformamide (DMF, 7.91 × 10−2), followed by cyclohexanone (2.810 × 10−2), 1,4-dioxanone (2.69 × 10−2), acetone (7.04 × 10−3), ethyl acetate (4.20 × 10−3), n-propanol (3.69 × 10−3), isobutanol (3.38 × 10−3), methanol (3.17 × 10−3), n-butanol (3.03 × 10−3), ethanol (2.83 × 10−3), isopropanol (2.69 × 10−3), and acetonitrile (1.15 × 10−2) at the temperature of 318.15 K. Similar results of solubility sequence from large to small were also obtained in other temperatures. The X-ray diffraction analysis illustrates that the crystalline forms of all samples were consistent, and no crystalline transformation occurred during the dissolution process. In aprotic solvents, except for individual solvents, the solubility data decreases with the decreasing values of hydrogen bond basicity (β) and dipolarity/polarizability (π*). The largest average relative deviation (ARD) data in the modified Apelblat equation is 1.9% and observed in isopropanol; the maximum data in λh equation is 4.3% and found in n-butanol. The results of statistical analysis show that the modified Apelblat equation is the more suitable correlation of experimental data for ethyl candesartan in selected mono solvents at all investigated temperatures. In addition, different parameters were used to quantify the solute–solvent interactions that occurred in the dissolution process including Abraham solvation parameters (APi), Hansen solubility parameters (HPi), and Catalan parameters (CPi).
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference33 articles.
1. Candesartan, angiotensin II type 1 receptor blocker is able to relieve age-related cognitive impairment;Pharmacol. Rep.,2018
2. Applying different techniques to improve the bioavailability of candesartan cilexetil antihypertensive drug;Drug Des. Dev. Ther.,2020
3. Qin, H.L., Liu, J., and Fan, X.Q. (2022). Synthesis Process for Candesartan Cilexetil. (Chinese Patent Application No. 113,912,588).
4. Naka, T., Nishikawa, K., and Kato, T. (1996). Benzimidazole Derivatives, Their Production and Use and Use as Angiotensin II Antagonists. (European Patent Application No. 0720982).
5. A novel and practical synthesis of substituted 2-ethoxy benzimidazole: Candesartan cilexetil;Tetrahedron,2010
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献